No products in the cart.
Pre-made Bapotulimab benchmark antibody ( Whole mAb, anti-ILDR2 therapeutic antibody, Anti-C1orf32/dJ782G3.1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-047
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bapotulimab biosimilar, Whole mAb, Anti-ILDR2 Antibody: Anti-C1orf32/dJ782G3.1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bapotulimab is a human/mouse cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody that exhibits anti-tumour activity by targeting, binding to and inhibiting ILDR2, and thereby blocking the immunosuppressive activity of ILDR2.
| Products Name (INN Index) | Pre-Made Bapotulimab biosimilar, Whole mAb, Anti-ILDR2 Antibody: Anti-C1orf32/dJ782G3.1 therapeutic antibody |
|---|---|
| INN Name | Bapotulimab |
| Target | ILDR2 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Bayer |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ILDR2 |
| Package |
Previous slide
Next slide
